Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients

Abstract Nonalcoholic fatty liver disease (NAFLD) refers to excess fat accumulation in the liver. In animal experiments and human kinetic study, we found that administration of combined metabolic activators (CMAs) promotes the oxidation of fat, attenuates the resulting oxidative stress, activates mi...

Full description

Bibliographic Details
Main Authors: Mujdat Zeybel, Ozlem Altay, Muhammad Arif, Xiangyu Li, Hong Yang, Claudia Fredolini, Murat Akyildiz, Burcin Saglam, Mehmet Gokhan Gonenli, Dilek Ural, Woonghee Kim, Jochen M Schwenk, Cheng Zhang, Saeed Shoaie, Jens Nielsen, Mathias Uhlén, Jan Borén, Adil Mardinoglu
Format: Article
Language:English
Published: Springer Nature 2021-10-01
Series:Molecular Systems Biology
Subjects:
CMA
multi‐omics
NAFLD
systems biology
Online Access:https://doi.org/10.15252/msb.202110459

Internet

https://doi.org/10.15252/msb.202110459

Similar Items